Conference abstract · 2019
Conference abstractPublished 27 Oct 2014
Increasing access with biosimilars
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Access is a function of accessibility (or reach), availability, acceptability (quality) and affordability. Developed nations have most dimensions addressed, leaving scope for improvement on affordability (yes, even where insurance exists) while developing nations face challenges along all dimensions Drugs enter the Access Ecosystem only on availability and affordability ? ie ? Are the drugs required to treat patients available where and when patients need them? ? Are the drugs affordable to the entire population? When we look at India today, even if biosimilars were to be easily available and somewhat affordable, we need to ask ourselves: ? How do we make sure there are enough physicians and paramedical staff to diagnose and treat patients with biologicals? ? How do we make sure that patients are getting the right treatments at the right time in the correct doses? ? How do we make sure that biologicals reach patients/hospitals where used/administered? ? How do we ensure that they are stored correctly through out their journey from the distributor to the end patient? ? Are we truly bring them within the reach of many and not just beyond the privileged few? ? What are the measures we have in place to make sure that the drugs are safe for patients to use? Only if we are addressing these questions will the true value of biosimilars be fully realised
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2018
How to increase biosimilar access and commercialization success
Article · 30 Oct 2025
The Evolving Role of Biosimilars in Enhancing Global Healthcare Access
Opinion · 29 Sep 2025
Biosimilars: Affordable Access, Enhanced Healthcare in Developing Nations
Short communication · 29 Aug 2025
Biosimilars: Cost Savings, Access, and Safe Integration
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Steven Lehrer”

